Bluejay Diagnostics
BJDX
4 hedge funds and large institutions have $243K invested in Bluejay Diagnostics in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, reducing their positions, and closing their positions.
89,976% more capital inflows, than outflows
Capital inflows: $607K | Capital outflows: $674
300% more funds holding
Funds holding: 1 → 4 (+3)
14.25% more ownership
Funds ownership: 1.85% → 16.09% (+14%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$434K |
| 2 |
Armistice Capital
New York
|
+$86.7K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$65K |
| 4 |
Tower Research Capital (TRC)
New York
|
+$21.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Coppell Advisory Solutions
Coppell,
Texas
|
-$674 |
BJDX Hedge Fund Activity: Q4 2023 in Review
4 of the 6,877 institutional investors tracked by Wall St. Rank reported a position in Bluejay Diagnostics (BJDX) for Q4 2023, worth a combined $243K — up 144% from $100K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new BJDX positions and 0 closed out — a net gain of 3 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Sabby Management, adding an estimated $434K. The largest seller was Coppell Advisory Solutions, cutting an estimated $674.
- 4 institutional investors held Bluejay Diagnostics (BJDX) as of Q4 2023, up from 1 in Q3 2023.
- Funds reported $243K of Bluejay Diagnostics stock for Q4 2023, up 144% quarter-over-quarter.
- 3 funds opened new Bluejay Diagnostics positions in Q4 2023 and 0 closed out, a net change of +3 holders.
- The largest Bluejay Diagnostics buyer in Q4 2023 was Sabby Management, an estimated $434K added.
- The largest Bluejay Diagnostics seller in Q4 2023 was Coppell Advisory Solutions, an estimated $674 sold.
Based on aggregated 13F filings for Q4 2023.